48.16 -0.13 (-0.27%)
After hours: 7:27PM EDT
|Bid||48.16 x 800|
|Ask||49.20 x 1800|
|Day's Range||47.78 - 49.78|
|52 Week Range||37.30 - 71.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.50|
The city of Madison is providing $2.6 million in tax increment financing to University Research Park for the project.
GREEN BAY, Wis. and MADISON, Wis., Aug. 13, 2018 /PRNewswire/ -- When the Green Bay Packers cross the 50-yard line this season, it will be meaningful both on and off the field. Cologuard donates $50 to the Vince Lombardi Cancer Foundation each time the Green Bay Packers cross the 50-yard line this season. Fans taking colon cancer screening pledge at Packers50.com can be entered to win luxury box tickets.
GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. Its cash position was at high enough levels to cover future operational needs. GlycoMimetics ended the second quarter (Jun. 30, 2018) with $229.4 million in cash.
Biotech stocks have been hot since the beginning of May, rising by about 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB), more than double the pace of the S&P 500's rise. Shares of Intercept Pharmaceuticals Inc. ( ICPT) have risen by more than 63% since the beginning of May, while recently posting better-than-expected quarterly results that beat on both the top and bottom lines. The stock has run into a level of technical resistance around $118, posing as the first issue. Additionally, the relative strength index is showing signs that the stock is now overbought, rising above 70 three times since the start of June.
MADISON, Wis., Aug. 6, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conference during August and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer.
NEW YORK, NY / ACCESSWIRE / August 3, 2018 / DexCom and Exact Sciences Corporation went in separate directions after reporting second quarter results. DexCom exploded and hit a new high after reporting an earnings beat while Exact Sciences slipped almost 13% after missing its revenue expectations. DexCom, Inc. shares closed up 30.65% on nearly 7 million shares traded.
Stock futures fell on U.S.-China trade war fears: Tesla stock soared on cash levels and profitability plans, Wynn Resorts and Exact Sciences also moved on earnings.
The company's stock dropped more than 10 points, or 21 percent, in after-hours trading, opening at $48.26.
BLAINE, Minn., Aug. 2, 2018 /PRNewswire/ -- Longtime PGA TOUR professional and colon cancer survivor, Tom Lehman, is teaming up with Fight Colorectal Cancer (Fight CRC) to help raise awareness of the nation's second-deadliest cancer. The one-year agreement, supported by Exact Sciences (EXAS), will feature Lehman wearing the Fight CRC logo on his hat, numerous public appearances, and a public service announcement campaign highlighting the importance of early detection and the options available for colon cancer screening, including accurate, non-invasive options.
The high-flying maker of Cologuard DNA tests fails to deliver in Q2 on sky-high revenue growth expectations.
On a per-share basis, the Madison, Wisconsin-based company said it had a loss of 30 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- More than 10,000 healthcare providers ordered their initial Cologuard test during the second quarter, and nearly 121,000 have ordered since the test was launched MADISON, Wis. , Aug. 1, 2018 /PRNewswire/ ...
Bring on healthcare earnings season. Ahead of earnings season for the group, we have selected three healthcare stocks beating the market in 2018. Using TipRanks' Stock Screener tool, we quickly discovered the best-rated stocks, filtering by "best analyst consensus" stocks in the healthcare sector.
Stock Research Monitor: CGIX, CHEK, and EXAS LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on DXCM sign up now at www.wallstequities.com/registration . Today's research on WallStEquities.com ...
MADISON, Wis. , July 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host webcasts and conference calls of its annual stockholders meeting and to discuss ...
Demand for its colon cancer screening solution continues to drive sales higher even as the company invests in next-generation screening.
Over the last month, growth of ETFs holding EXAS is favorable, with net inflows of $6.26 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.
This survey of 358 nurse practitioners (NPs) showed they are highly engaged in colorectal cancer (CRC) screening, both personally and on behalf of their patients. Most NPs aged 50 years and older who were surveyed (91 percent, n=209) reported being screened for CRC as recommended by leading guidelines.
NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PDL ...
As concerns over trade wars escalate, investors may find refuge in small-cap stocks, which have been handily beating the broader market this year. Lower exposure to trade risk along with beneficial tax policy exposures, relative strength in U.S. economic growth, and potential merger activity, make small caps like GrubHub Inc. ( GRUB), Exact Sciences Corp. ( EXAS) and Aspen Technology Inc. ( AZPN), especially attractive in the current environment, according to CNBC.
MADISON, Wis., June 19, 2018 /PRNewswire/ -- The national colon cancer screening movement led by golfer Jerry Kelly will be front and center when the PGA TOUR Champions comes to University Ridge Golf Course June 22-24, 2018 for the American Family Insurance Championship (AmFam Championship). Today, the American Family Insurance Championship and Exact Sciences announced an expanded partnership that makes the Madison-based company and its noninvasive colon cancer screening test, Cologuard, one of the leading partners of the 2018 event.